Is rblx a solid long term investment?
Traded publicly as RBLX, it is a stock that a lot of people have been seriously considering as a long-term stock option, especially recently. That said, you have to be careful when it comes to choosing your long-term stock options because if you choose the wrong ones, the portfolio isn’t going to perform the way that you want it to.
Should you buy Roblox stock right now?
Long-term, metaverse stocks will be just fine. But in the near term, some metaverse stocks may struggle. And one we’re concerned about is Roblox stock. To be clear, we are very bullish on Roblox stock in the long run. It’s a holding in our flagship Innovation Investor portfolio.
How to buy Robux stock?
Method 2 Method 2 of 2: Using a Phone or Tablet
- Open Roblox on your Android, iPhone, or iPad. It's the icon with two Roblox characters that says "ROBLOX" inside.
- Tap the R$ icon. It's near the top-right corner. ...
- Tap the amount of Robux you want to buy. The price for each package appears next to the amount of Robux you're buying.
- Follow the on-screen instructions to pay for your Robux. ...
How much does Roblox cost?
The three Roblox Premium packages are: Premium 450 For $4.99 per month, you receive 450 Robux each month. Premium 1000 The $9.99 subscription guarantees you 1,000 Robux every month. Premium 2200 Paying $19.99 every month you will receive 2,200 Robux. All premium members enjoy extra benefits which non-subscribers don’t access.
Should I buy or sell Renalytix stock right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Renalytix in the last year. There are currently 4 buy ratings for the stoc...
What is Renalytix's stock price forecast for 2022?
4 equities research analysts have issued 1 year price objectives for Renalytix's shares. Their forecasts range from $8.00 to $38.00. On average, th...
How has Renalytix's stock price performed in 2022?
Renalytix's stock was trading at $15.90 on January 1st, 2022. Since then, RNLX stock has decreased by 73.3% and is now trading at $4.25. View the...
When is Renalytix's next earnings date?
Renalytix is scheduled to release its next quarterly earnings announcement on Tuesday, June 21st 2022. View our earnings forecast for Renalytix .
How were Renalytix's earnings last quarter?
Renalytix Plc (NASDAQ:RNLX) announced its quarterly earnings results on Thursday, March, 31st. The company reported ($0.21) earnings per share for...
Who are Renalytix's key executives?
Renalytix's management team includes the following people: Mr. James R. McCullough M.B.A. , CEO & Exec. Director (Age 54, Pay $1.13M) Mr. Fergus...
Who are some of Renalytix's key competitors?
Some companies that are related to Renalytix include Invitae (NVTA) , Castle Biosciences (CSTL) , Viridian Therapeutics (VRDN) , Burning Rock B...
What other stocks do shareholders of Renalytix own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include Ampio Pharmaceuticals (AMP...
When did Renalytix IPO?
(RNLX) raised $156 million in an initial public offering on Friday, July 17th 2020. The company issued 11,000,000 shares at a price of $14.22 per s...
What is MarketBeat community ratings?
What is the P/E ratio of Renalytix?
MarketBeat's community ratings are surveys of what our community members think about Renalytix AI and other stocks. Vote “Outperform” if you believe RNLX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RNLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is Renalytix AI?
The P/E ratio of Renalytix AI is -44.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does Renalytix pay dividends?
Renalytix AI plc develop s artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. Renalytix AI plc was founded in 2018 and is based in Cardiff, the United Kingdom.
What is Renalytix AI?
Renalytix AI does not currently pay a dividend.
Is RNLX bullish or bearish?
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was founded in 2018 and is based in London, the United Kingdom.
When was Renalytix AI founded?
3 Wall Street analysts have issued ratings. Currently, 2 analysts rated RNLX as Bullish, 0 rated it Bearish, and 1 rated it Neutral for a Wall Street consensus of buy. View RNLX’s ratings here. 1 Seeking Alpha authors also rated the stock, and their ratings often outperform those of Wall Street analysts. Here are their ratings on RNLX
Is Renalytix listed on the NASDAQ?
The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was founded in 2018 and is based in London, the United Kingdom.
Does RNLX pay dividends?
Renalytix Plc is listed on the NASDAQ as (NASDAQ:RNLX).
